Ensuring Access to Generic Medications Act

Bill 118 s 1128, also known as the Ensuring Access to Generic Medications Act, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to increase access to generic medications for consumers by addressing certain barriers that may prevent generic drugs from coming to market.

One key provision of the bill is the establishment of a process for generic drug manufacturers to obtain samples of brand-name drugs in order to conduct bioequivalence testing. This testing is necessary for generic drugs to receive approval from the Food and Drug Administration (FDA) and enter the market. By streamlining this process and ensuring that generic manufacturers have access to the samples they need, the bill aims to promote competition and lower drug prices for consumers.

Additionally, the bill includes measures to prevent brand-name drug manufacturers from using tactics to delay the entry of generic drugs into the market. This includes prohibiting certain agreements between brand-name and generic manufacturers that may delay the availability of generic medications. Overall, the Ensuring Access to Generic Medications Act seeks to promote competition in the pharmaceutical industry and increase access to affordable medications for consumers. By addressing barriers to the entry of generic drugs into the market, the bill aims to lower drug prices and improve access to essential medications for all Americans.